HR Execs on the Move


 
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.tilray.com
  • 1100 Maughan Road
    Nanaimo, BC CAN V9X 1J2
  • Phone: 844.845.7291

Executives

Name Title Contact Details
Nathan Webb
Director of Commercial Finance Profile
Beth Carreon
Vice President of Finance Profile
Rita Seguin
Executive Vice President of Human Resources Profile
Rita Seguin
Chief Human Resources Officer Profile
Andrea Fraser
Director of Global Human Resources Profile

Similar Companies

Ascend Therapeutics

Ascend Therapeutics is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Action Behavior Centers

Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.

Synergy Pharmaceuticals

Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.

Symphogen

Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.